AONN+ 2020 Midyear Virtual Conference

May 15, 2020 ‐ May 17, 2020


The Academy of Oncology Nurse & Patient Navigators (AONN+) is converting the 2020 AONN+ Midyear Conference to a virtual experience. Although times are uncertain, this change is an exciting addition to the capabilities offered through AONN+. The event will occur as scheduled on May 14-17, 2020. All current registrations will be transferred to the new, virtual format, and the agenda will continue to feature high-level faculty, engaging disease state discussions, practical solutions to daily navigation challenges, and accredited content.

Packages Display Packages

Sessions Included:

Preconference Session: Policy and Advocacy Boot Camp ()

Preconference Session: We Treat Everyone the Same - Fostering Health Equity for Sexual & Gender Minorities ()

Empower Your Female Patients: Navigating GYN Malignancies ()

Navigating Your Patient Through Thoracic Cancer ()

Emerging Roles of Germline and Tissue Genetic Testing: A Primer for Navigators ()

Shared Decision Making Who CARES about Empowering Patients to be Active Participants in the Healthcare System ()

What’s Hot in Integrative Therapies: Mind and Body Healing for Your Patients ()

A message from AONN+ Program Director Sharon Gentry (May 15, 2020 12:30 PM)

Industry Sponsored Session Presentation by Wellstat Therapeutics (May 15, 2020 12:30 PM)

Welcome to AONN+ Midyear Virtual Conference (May 15, 2020 01:30 PM)

Thank You to Our Sponsors and Partners (May 15, 2020 02:00 PM)

General Session 1 | Cancer and Mental Health: Lightening the Load for Patients and Families (May 15, 2020 02:00 PM)

A Look At AONN+ Membership (May 15, 2020 03:15 PM)

General Session 2 | Spread the Word: Early Detection and Screening Saves Lives (May 15, 2020 03:15 PM)

Networking with Exhibitors (May 15, 2020 04:15 PM)

Industry Sponsored Session Presentation by Eli Lilly (May 15, 2020 04:30 PM)

Industry Sponsored Session Presentation by Bristol-Myers Squibb (May 16, 2020 08:15 AM)

What You Need To Know About AONN+ Certification (May 16, 2020 09:00 AM)

General Session 3 | Vaping the New Epidemic (May 16, 2020 09:15 AM)

Leveraging the AONN+ Local Navigator Networks (May 16, 2020 10:15 AM)

General Session 4 | Mechanisms of Action – Integrating Biosimilars in Cancer Treatment (May 16, 2020 10:30 AM)

Networking with Exhibitors (May 16, 2020 11:30 AM)

General Session 5 | Patient Navigation and COVID-19 (May 16, 2020 01:00 PM)

What’s New? AONN+ initiatives (May 16, 2020 02:00 PM)

General Session 6 | Treatments, Support and Quality of Life for Patients with Metastatic Disease (May 16, 2020 02:15 PM)

Accessing the AONN+ COVID-19 Toolkit (May 16, 2020 03:15 PM)

General Session 7 | The Role of the Navigator: Identifying Gaps and Facilitating Improvements in Patient Care (May 16, 2020 03:30 PM)

Networking with Exhibitors (May 16, 2020 04:30 PM)

Industry Sponsored Session Presentation by Janssen (May 16, 2020 04:45 PM)

General Session 8 | Fertility Preservation (May 17, 2020 09:00 AM)

Getting Social With AONN+ (May 17, 2020 10:00 AM)

General Session 9 | Team Based Care: Understanding Compassion Fatigue and Burnout Amongst Nurse and Patient Navigators (May 17, 2020 10:15 AM)

Spotlight On AONN+ Tools And Resources (May 17, 2020 11:15 AM)

General Session 10 | Direct-To-Consumer (DTC) Genetic Testing: What the Journals Report, How the Media Covers It, & How It Affected Patients (May 17, 2020 11:30 AM)

Final thoughts from Program Director Sharon Gentry (May 17, 2020 12:30 PM)

General Session 11 | Read. Feel. Create. Heal: Supporting Children of Parents with Cancer | Closing Remarks (May 17, 2020 12:45 PM)

Standard: $115.00

Sessions

Industry Sponsored Session Presentation by Wellstat Therapeutics

May 15, 2020 12:30pm ‐ May 15, 2020 1:30pm

Identification: FRI02

Urgent Treatment of Early-Onset Severe Toxicity of 5-FU or Capecitabine

OBJECTIVES

  • Describe the incidence and burden of early-onset severe toxicity in patients receiving 5-FU and capecitabine
  • Describe mechanism of action of 5-FU and its cytotoxic metabolites as it relates to the causes of early-onset severe toxicity
  • Recognize signs and symptoms of 5-FU and capecitabine early-onset severe toxicity
  • Summarize evidence supporting emergency treatment for patients with early-onset severe toxicity and following 5-FU or capecitabine overdoses
  • Review the importance of prompt treatment of overdoses and early-onset severe toxicity
  • Educate patients, caregivers, and colleagues about the importance of recognizing and urgently treating early-onset severe toxicity of 5-FU or capecitabine

Speaker:

custom image
Alice Beers, BSN, OCN, RN-BC
Oncology Nurse Navigator
MedStar Georgetown Cancer Network at Washington Cancer Institute
MedStar Washington Hospital Center
Washington, DC

Standard: $15.00

Welcome to AONN+ Midyear Virtual Conference

May 15, 2020 1:30pm ‐ May 15, 2020 2:00pm

Identification: FRI03

AONN+ Conference Planning Committee and Leadership welcome you all to the AONN+ 2020 Midyear Virtual Conference!

Speaker(s):
  • Peg Rummel, RN, MHA, OCN, NE-BC, Oncology Nurse Navigator, Abramson Cancer Center
  • Penny Daugherty, RN, MS, OCN, ONN-CG, Oncology Nurse Navigator, Northside Hospital
  • Danelle Johnston, MSN, RN, HON-ONN-CG, OCN, Senior Vice President, Mission Delivery, Cancer Support Community
  • Monica Dean, HON-OPN-CG, Director of Patient Navigation Program Development, Academy of Oncology Nurse & Patient Navigators
  • Emily Gentry, BSN, RN, HON ONN-CG, OCN, Senior Director of Education and Program Development, Academy of Oncology Nurse & Patient Navigators
  • Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators
  • Lillie D. Shockney, RN, BS, MAS, HON-ONN-CG, Editor-in-Chief, JONS; Co-Founder University Distinguished Service Professor of Breast Cancer, Professor of Surgery, Co-Developer, Work Stride-Managing Cancer at Work, Johns Hopkins Healthcare Solutions, Academy of Oncology Nurse & Patient Navigators
Standard: $15.00

General Session 1 | Cancer and Mental Health: Lightening the Load for Patients and Families

May 15, 2020 2:00pm ‐ May 15, 2020 3:15pm

Identification: FRI05

This session will provide an overview of how healthcare providers can support patients with preexisting mental health disorders. It will offer resources that are effective when supporting cancer patients who have depression, anxiety, and a preexisting mental health disorder.

Upon completion of the session, participants will be able to:

  • Define the role of mental health in cancer outcomes.
  • Identify the effects of a cancer diagnosis on mental health.
  • Provide resources to manage the mental health consequences of a cancer diagnosis.

Speaker(s):
  • Jennifer Bires, MSW, LICSW, OSW-C, Clinical Social Worker, Patient Centered Care, GW Cancer Center
Standard: $15.00

General Session 2 | Spread the Word: Early Detection and Screening Saves Lives

May 15, 2020 3:15pm ‐ May 15, 2020 4:15pm

Identification: FRI07

Speaker(s):
Standard: $15.00

Industry Sponsored Session Presentation by Eli Lilly

May 15, 2020 4:30pm ‐ May 15, 2020 5:15pm

Identification: FRI09


A Treatment Option for Patients With HR+, HER2- Advanced or Metastatic Breast Cancer 

Presented by Kristi K. Orbaugh, RN, MSN, RNP, AOCN

 

If you have any questions about a Lilly product, please call 1-800-LillyRx (1-800-545-5979).

Standard: $15.00

Industry Sponsored Session Presentation by Bristol-Myers Squibb

May 16, 2020 8:15am ‐ May 16, 2020 9:15am

Identification: SAT01

CAR T Cell Therapy – Consider a Nurse’s Perspective

Presented by Jean Treacy MS, APRN-BC

Learn more about the potential of CAR T cell therapy. This presentation will help you understand the science behind this immunotherapy treatment and its ability to fight certain cancers. You’ll learn about the CAR T cell therapy patient journey, as well as the multidisciplinary treatment team that supports them. The presentation will close with how to monitor and manage select side effects of treatment. This presentation does not discuss any specific CAR T cell therapies.

This is a Bristol Myers Squibb-Sponsored program and no Continuing Medical Education credits are offered.

Standard: $15.00

General Session 3 | Vaping the New Epidemic

May 16, 2020 9:15am ‐ May 16, 2020 10:30am

Identification: SAT03

This presentation will discuss the current state of smoking in the United States and how e-cigarettes factor into the smoking picture. Types of e-cigarettes, contents in a vaping pod, and current evidence of vaping’s effects on people, especially youth and vulnerable adults. Guidance for clinicians in discussing e-cigarettes with their patients, including the pros and cons of e-cigarettes as a smoking-cessation method. Advocacy efforts to restrict e-cigarette use in young adults in schools, at the state and local levels. Resources will be provided to learn more, as well as materials for use in educating patients, parents, and youth on the issues of e-cigarettes.

Upon completion of the session, participants will be able to:

  • List 3 reasons e-cigarettes are a poor tool to help quit smoking
  • Discuss the harmful substances in e-cigarettes and their impact on smoking addiction, health
  • Verbalize what populations are most at risk for addiction to e-cigarettes/smoking and why and the health harms to these populations

Speaker(s):
Standard: $15.00

General Session 4 | Mechanisms of Action – Integrating Biosimilars in Cancer Treatment

May 16, 2020 10:30am ‐ May 16, 2020 11:30am

Identification: SAT05

This session will discuss biosimilars, their mechanism of action, and how to incorporate their use in patient treatments. Focus will be drawn on cost benefits and challenges encountered related to approval of biosimilars and how creation of more biosimilars will affect the pharmaceutical landscape.

Upon completion of the session, participants will be able to:

  • Define what is considered a biosimilar
  • Discuss biosimilars’ mechanism of action
  • Increase awareness on when incorporating biosimilars into treatments plans is beneficial
  • Discuss the process of obtaining coverage and funding/coverage for biosimilars

Speaker(s):
Standard: $15.00

General Session 5 | Patient Navigation and COVID-19

May 16, 2020 1:00pm ‐ May 16, 2020 2:15pm

Identification: SAT07

Speaker(s):
  • Sharon S. Gentry, MSN, RN, HON-ONN-CG, AOCN, CBCN, Program Director, Academy of Oncology Nurse & Patient Navigators
Standard: $15.00

General Session 6 | Treatments, Support and Quality of Life for Patients with Metastatic Disease

May 16, 2020 2:15pm ‐ May 16, 2020 3:30pm

Identification: SAT09

This session will help define the basics, treatment, and goals of metastatic disease so that patient, community, and clinical navigators can recognize the specific needs and goals of these patients and be prepared to assist, educate, and support them.

Upon completion of the session, participants will be able to:

  • Understand the basics of metastasis and the various treatment options and rationale for metastatic patients to best support them in making decisions about individual treatment
  • Understand patient (and caregiver) emotional issues of uncertainty, fear, anxiety, and general coping skills to adequately support specific needs
  • Assist patients and caregivers to optimize the myriad essentials of survivorship and quality of life in this patient population
  • Describe the role of integrative therapies in helping patients live with metastatic disease

Speaker(s):
Standard: $15.00